HSV disease is distributed worldwide. Anti-herpesvirus drugs are a problem in clinical settings, particularly in immunocompromised individuals undergoing herpes simplex virus type 1 infection. In this work, 4-substituted-1,2,3-1H-1,2,3-triazole linked nitroxyl radical derived from TEMPOL were synthesized, and their ability to inhibit the in vitro replication of HSV-1 was evaluated. The nitroxide derivatives were characterized by infrared spectroscopy and elemental analysis, and three of them had their crystal structures determined by single-crystal X-ray diffraction. Four hybrid molecules showed important anti-HSV-1 activity with IC50 values ranged from 0.80 to 1.32 µM. In particular, one of the nitroxide derivatives was more active than Acyclovir (IC50 = 0.99 µM). All compounds tested were more selective inhibitors than the reference antiviral drug. Among them, two compounds were 4.5 (IC50 0.80 µM; selectivity index CC50/IC50 3886) and 7.7 times (IC50 1.10 µM; selectivity index CC50/IC50 6698) more selective than acyclovir (IC50 0.99 µM; selectivity index CC50/IC50: 869). These nitroxide derivatives may be elected as leading compounds due to their antiherpetic activities and good selectivity.

中文翻译：

---

4-取代-1H-1,2,3-三唑-硝酰基连接杂合体的化学和抗单纯疱疹病毒1型评估。


HSV疾病分布于世界各地。抗疱疹病毒药物在临床环境中是一个问题，特别是对于感染 1 型单纯疱疹病毒的免疫功能低下的个体。在这项工作中，合成了源自TEMPOL的4-取代-1,2,3-1H-1,2,3-三唑连接的硝酰自由基，并评估了它们抑制HSV-1体外复制的能力。通过红外光谱和元素分析对硝基氧衍生物进行了表征，并通过单晶X射线衍射确定了其中三种硝基氧衍生物的晶体结构。四种杂合分子显示出重要的抗 HSV-1 活性，IC50 值范围为 0.80 至 1.32 µM。特别是，其中一种硝基氧衍生物比阿昔洛韦 (Acyclovir) 活性更高 (IC50 = 0.99 µM)。所有测试的化合物都是比参考抗病毒药物更具选择性的抑制剂。其中，两种化合物的选择性比阿昔洛韦（IC50 0.99 µM；选择性指数 CC50/IC50：869）高 4.5 倍（IC50 0.80 µM；选择性指数 CC50/IC50 3886）和 7.7 倍（IC50 1.10 µM；选择性指数 CC50/IC50 6698）。 ）。这些硝基氧衍生物因其抗疱疹活性和良好的选择性而可能被选为先导化合物。